Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase-2, Multi-centre, Prospective, Randomized, Standard-of-care Plus Placebo-controlled, Patient and Central Evaluator Blinded, Parallel Arm, Clinical Study to Evaluate Safety, Tolerability and Efficacy of the AUP1602-C as Treatment for Non-healing Neuro-ischemic DFU

Next Previous
Trial Profile

Phase-2, Multi-centre, Prospective, Randomized, Standard-of-care Plus Placebo-controlled, Patient and Central Evaluator Blinded, Parallel Arm, Clinical Study to Evaluate Safety, Tolerability and Efficacy of the AUP1602-C as Treatment for Non-healing Neuro-ischemic DFU

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUP 16 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DIAMEND; DIAMEND STUDY
  • Sponsors Aurealis Therapeutics

Most Recent Events

  • 13 Nov 2024 According to an Aurealis Therapeutics media release, company raises CHF 8 Million and the funds will be primarily used to complete Phase 2 clinical studies
  • 04 Nov 2024 According to an Aurealis Therapeutics media release, company continues to progress the development of AUP-16, which has now reached the Last Patient Last Treatment milestone in its ongoing Phase 2 "DIAMEND" study.
  • 11 Mar 2024 According to media Aurealis Therapeutics release, company announced the successful recruitment and randomization of half of the patients expected to participate in its DIAMEND AUP-16 Phase-2 clinical trial on Diabetic Foot Ulcers (DFUs). These 30 patients are expected to complete the 12-week treatment in May 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top